Phenom Study: First Benchmark of European 100 Uncovers Opportunities to Meet Job Candidates’ High Expectations
8.6.2022 15:00:00 EEST | Business Wire | Press release
Phenom, the global leader in Talent Experience Management (TXM), released its first-ever State of Candidate Experience Report — European Edition. The comprehensive audit, which assessed the top 100 European companies on the Fortune Global 500 list in three key areas of the talent journey — attraction, engagement and conversion —revealed there is significant room to improve the experience with personalisation and automation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220608005302/en/
Inaugural European Edition: State of Candidate Experience Report Provides Recommendations for Improvements (Graphic: Business Wire)
Talent acquisition is now a business priority among the C-suite — especially across industries with high-volume hiring needs — such as healthcare, hospitality, manufacturing, retail and transportation. But instead of using personalisation and automation technology to effectively and efficiently scale hiring, the majority of European 100 companies are falling short.
The 2022 audit of European 100 career sites reveals:
- Only 9% had an intuitive job search and application process
- Only 10% sent applicants a satisfaction survey
- Only 6% had a recruitment chatbot
- 96% did not present job recommendations based on browsing history
- 90% did not display recently viewed jobs
- 68% lacked a job cart or favorites function to save jobs
- 0% communicated application status beyond initial confirmation
How Companies Can Improve the Candidate Experience
Simplify search and apply. Requiring three or more clicks to apply for a job is a major roadblock for candidates. The longer it takes for a candidate to find and apply to a relevant job, the greater the chance they will abandon the process and look elsewhere. One recommendation is for companies to equip their career sites with the ability to provide relevant suggested jobs based on a candidate’s keywords, skills, experience and location.
Create hyper-personalisation. Candidates are used to superior tailored experiences in their consumer lives. If finding a job that matches what they want is difficult, they are quick to move on. Dynamic personalisation is one way companies can automatically match a candidate’s preferences, experience, skills and location with best-fit job openings — and surface content for candidates as they move through their own unique end-to-end talent journey across multiple channels.
Automate communication. Job seekers want to know where they stand in the screening and interview scheduling process. Failure to communicate status details jeopardises employer brand and acceptance rates. Using conversational AI chatbots, SMS and email campaigns are a few ways companies can automate individualised communications to keep job seekers engaged while differentiating their brand.
“Hiring, developing and retaining talent isn’t just an HR priority — it is a business priority. Companies must differentiate themselves by the experiences they provide to their candidates and their employees to sustain,” said Mahe Bayireddi, CEO and co-founder of Phenom. “This benchmark report of the European 100 provides industry-specific insights and actionable recommendations for using automation and personalisation to earn and keep top talent.”
How Automation Helps Talent Experiences
Automation enables a quick, efficient hiring process that serves up best-fit jobs to candidates — and best-fit candidates to recruiters — while optimising omnichannel communications that nurture talent communities. Not only do job seekers appreciate a streamlined, personalised experience, but with efficiency at the core, recruiters and hiring managers benefit from decreased time to fill and better long-term fits.
Employees are no exception. The same hyper-personalised candidate experience should extend to internal talent, who may be looking to move within their current company. By making relevant open roles and development opportunities visible, actionable and attainable, companies stand a better chance at retaining them. AI-powered talent marketplaces automate the process for an employee experience that unifies all key stakeholders: internal candidates, recruiters and hiring managers.
With this report, companies can learn how to make changes — large or small — to enhance the candidate experience and provide a measurable, positive impact on their businesses.
Download the full 2022 State of the Candidate European Edition report and rankings here. Also recently published, the sixth annual report auditing the Fortune 500 is available for download here. Organisations can request their own complimentary career site audit here.
To request a demo of Phenom TXM visit phenom.com.
About Phenom
Phenom has a purpose of helping a billion people find the right job. Through AI-powered talent experiences, HR teams are using Phenom to hire employees faster, develop them to their full potential, and retain them longer. The Phenom Talent Experience Management (TXM) platform seamlessly connects candidates, employees, recruiters, and managers — empowering over 500 diverse and global enterprises with innovative products including Phenom Career Site, Chatbot, CMS, CRM, AI Scheduling, Video Assessments, Campaigns, University Recruiting, Talent Marketplace, Career Pathing, Gigs, Mentoring, and Referrals.
Phenom was ranked among the fastest-growing technology companies in Deloitte Technology's Fast 500 for four years in a row, has been recognized in Business Intelligence Group's 2021 and 2022 Artificial Intelligence Excellence Awards and won a regional 2020 Timmy Award for launching and optimizing HelpOneBillion.com.
Headquartered in Greater Philadelphia, Phenom also has offices in India, Israel, the Netherlands, Germany and the United Kingdom.
For more information, please visit www.phenom.com. Connect with Phenom on LinkedIn, Twitter, Facebook, YouTube and Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220608005302/en/
Contact information
Media
Jannes Zwirner I jannes.zwirner@tonka-pr.com I +49.172.3650385
Julia Trzinski I julia.trzinski@tonka-pr.com I +49.179.6178513
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 09:07:00 EET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 09:00:00 EET | Press release
Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers across Europe to bring advanced proton treatment to their patients. “With both FDA clearance and CE Marking now in hand, the MEVION S250-FIT is
Bureau Veritas: Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 08:30:00 EET | Press release
Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2024, › Free Cash Flow of EUR 824.2 million, up 3.9% organically and up 2.6% at constant currency, and cash conversion of 107%2, › Adjusted net
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 08:00:00 EET | Press release
Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat in a mouse model in Sandhoff disease, a form of GM2 gangliosidosis with no approved treatments—alongside healthy control subjects. The research assessed how the drug’s exposure relates to its effects in the brain, demonstrating a significant increase in both survival (22%; 26 days) and assessments of movement and behavior at 16 weeks versus un
Galderma Announces Triple Approval of New State-of-the-Art Restylane ® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 08:00:00 EET | Press release
Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-art syringe for use with its NASHA® lidocaine range of Restylane products in multiple facial indications including the cheeks, nose, chin, jawline, tear troughs, nasolabial folds, marionette lines, as well as in the hands.1-3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224651688/en/ The syringe features a next-generation ergonomic design that enhances precision and control; includes an optimized syringe-needle connection with the new Terumo K-Pack Enhance™ needle; and offers a premium color-coded packaging and syringe design to support easy range navigation for practitioners.4-7, 9,10 It sets a new standard in Injectable Aesthetic devices and demonstrates Galderma’s unwavering commitment to driving innovation to meet the needs of both practitioners and patients. “Developing this new syringe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom